KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Equity (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Return on Equity for 12 consecutive years, with 0.61% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity fell 30.0% to 0.61% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.61%, a 30.0% decrease, with the full-year FY2025 number at 0.52%, down 23.0% from a year prior.
  • Return on Equity was 0.61% for Q4 2025 at Xenon Pharmaceuticals, down from 0.52% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.14% in Q2 2022 to a low of 0.61% in Q4 2025.
  • A 5-year average of 0.26% and a median of 0.22% in 2021 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: increased 11bps in 2022, then decreased -30bps in 2025.
  • Xenon Pharmaceuticals' Return on Equity stood at 0.2% in 2021, then increased by 14bps to 0.17% in 2022, then tumbled by -31bps to 0.22% in 2023, then plummeted by -38bps to 0.31% in 2024, then plummeted by -97bps to 0.61% in 2025.
  • Per Business Quant, the three most recent readings for XENE's Return on Equity are 0.61% (Q4 2025), 0.52% (Q3 2025), and 0.42% (Q2 2025).